EORTC

European Organisation for #Research and #Treatment of #Cancer defines better treatments for all cancer #patients to prolong survival and improve quality of life

[EORTC @EORTC]

📅 Save the date!

EORTC events are back in 2026 ⬇️

#CancerResearch #ClinicalTrials #Oncology #EORTCevents

[EORTC @EORTC]

#WorldCancerResearchDay celebrates the impact of cancer research and the collaboration behind progress against cancer.
EORTC is proud to host the World Cancer Research Day International Event on 23 September in Brussels and support this global initiative.

https://t.co/sghlkfLPyr

[EORTC @EORTC]

We honour the memory of Prof. Neil Aaronson, founding member of the EORTC Quality of Life Group & a pioneer of quality of life research in oncology.

His legacy continues to shape cancer research & improve the lives of patients worldwide.
Read our tribute: https://t.co/vECt7hGhAl

[EORTC @EORTC]

On #WRAD2026, we're celebrating a major milestone for radiotherapy research: 1,000 patients have now been enrolled in the ReCare cohort of the #EORTC - #ESTRO E²-RADIatE platform 🎉

Thank you to all the patients, investigators and study teams making this possible.

#ReCare

[EORTC @EORTC]

📢 New results from EORTC 1419 (ETERNITY): 78% of long-term survivors of grade 4 gliomas showed neurocognitive impairment, yet cognitive functioning remained largely stable over time. Findings support tailored counselling and long-term survivorship care.
https://t.co/pZ52AcbUrg

[EORTC @EORTC]

💬 What matters most to older adults with cancer?

A new EORTC perspective calls for patient preferences to be considered alongside survival, toxicity and quality of life in clinical trials.

🔗https://t.co/IdcKzI15Ci

#CancerResearch #OlderAdults #QualityofLife @EORTC_QLG

[EORTC @EORTC]

Fabio Borges presented a Spotlight Poster at #ISPE2026 in Milan.The study reviewed 264 extensions of indication for anticancer medicines approved in the EU (2011-2025), identifying over 1,000 benefit-risk uncertainties, with efficacy-related uncertainties being the most frequent.

[EORTC @EORTC]

📢 Join EORTC as a Fellow in the Quality of Life Department and contribute to methodological research on patient-reported outcomes (PROs) in cancer clinical trials.

🔗Apply here: https://t.co/z7GcIxqIv4

#EORTC #CancerResearch

[EORTC @EORTC]

Congratulations to our colleague Dagmara Kulis on her election to the @ISOQOL Board of Directors! 🎉

We are proud to see EORTC expertise helping advance #QualityofLife and patient-centred outcomes research.

Best wishes to Dagmara and the new Board for a successful term.

[ISOQOL @ISOQOL]

ISOQOL members have elected a President-Elect and three new Directors-at-Large to serve on the Board of Directors. They will begin their term following the 2026 Annual Conference. Please give a warm welcome to Dr. Weinfurt, Mrs. Kulis, Dr. Kwon, and Dr. Rodriguez-Leboeuf!

[EORTC @EORTC]

Part five of our ECRF 50th anniversary story is live.

For 50 years, people, philanthropy and science have come together to advance cancer research and improve outcomes for patients.

👉 Read the latest chapter: https://t.co/AjCyBJ2Mhk

#ECRF50 #CancerResearch #EORTC

[EORTC @EORTC]

🗣️ Understanding life after cancer

A new international study validates the EORTC QLQ‑SURV100, a questionnaire designed to assess #QualityofLife in cancer survivors across different cancer types, countries and cultures.

🔗 https://t.co/2lCdUDnB0F

#CancerResearch @EORTC_QLG

[EORTC @EORTC]

Part four of our EORTC Cancer Research Fund (ECRF) 50th anniversary story is live.

Discover how our Honorary Presidents have played a key role supporting the advancement of cancer research.

👉 Read the latest chapter: https://t.co/jpHNF70UMW

#ECRF50 #CancerResearch #EORTC

[EORTC @EORTC]

Through strategic investment in research, support for researchers and patients, and the development of high-quality evidence, EORTC's work continues helping advance clinical cancer research and inform better patient care.
🔗 Explore the Annual Report 2025: https://t.co/lA1dwKtQY5

[EORTC @EORTC]

🎗️ Tomorrow is #WorldLungCancerDay.

A recent Lung Cancer publication shows that the EORTC QLQ-C30 and QLQ-LC29 capture many common patient-reported symptomatic adverse events in #NSCLC, supporting the use of PROs alongside clinician-reported assessments.

https://t.co/pZ52AcbUrg

[EORTC @EORTC]

An important reflection on the impact of patient-reported outcomes (PROs) in oncology and the future of quality of life assessment. 👇

#QualityofLife #CancerResearch

[EORTC Quality of Life Group (QLG) @EORTC_QLG]

🗣️ Giving patients a voice in cancer care.
This new publication in EJC reflects on the @EORTC #QualityofLife Group's achievements and future priorities to ensure patient-reported outcomes remain central to cancer research and care.
🔗 https://t.co/3L9v6DtGbV
#GivingVoice2Patients

[EORTC Quality of Life Group (QLG) @EORTC_QLG]

🔍 New @EORTC #QualityofLife publication.

The new EORTC QLQ‑VU34 was developed to assess quality of life in women with vulva cancer.

Cross-cultural testing in 9 countries showed high relevance, acceptability & comprehensiveness.

🔗 https://t.co/ba4bDUEiyb
#GivingVoice2Patients

[EORTC @EORTC]

A new review in the European Journal of Cancer, led by EORTC, analysed 53 randomised pragmatic oncology trials.

🔬 Surrogate endpoints remained the most common primary endpoints, ahead of overall survival and quality of life.

🔗Read more: https://t.co/pZ52AcbUrg
#CancerResearch

[EORTC @EORTC]

Final results from the EORTC SPECTA Arcagen study and @ERN_EURACAN highlight the value of molecular profiling in rare cancers.

🔬 69.4% of patients had actionable alterations, identifying personalised treatment opportunities.

🔗 Read more: https://t.co/s2xQoCuEmi

[EORTC @EORTC]

EORTC is launching BRACE, a new clinical study evaluating radiotherapy as a bladder-preserving alternative for high-risk, non-muscle-invasive #BladderCancer after BCG treatment failure.

Thanks to Kom op tegen Kanker, Rising Tide and the study team for supporting this research.

[EORTC @EORTC]

New publication on peritoneal mesothelioma highlights the value of molecular profiling for identifying potential treatment opportunities in this rare cancer.

Congrats to Julien Péron, Nazim Benzerdjeb, Jean-Yves Blay, Marie Morfouace & collaborators.

🔗 https://t.co/nYQA14iBhs

[EORTC Quality of Life Group (QLG) @EORTC_QLG]

Recent expert commentary led by @SCSodergren in Hospital Healthcare Europe highlights the importance of age-appropriate HRQOL assessment in Adolescents & Young Adults (AYAs) with cancer & the role of the @EORTC QLQ-AYA30.

🔗 https://t.co/u82fmRBwB5
#CancerResearch #QualityofLife